Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Adamas Pharmaceuticals, Inc. (ADMS)

8.22   0 (0%) 12-31 19:00
Open: 8.24 Pre. Close: 8.22
High: 8.25 Low: 8.18
Volume: 3,151,400 Market Cap: 0(M)

Technical analysis

as of: 2022-01-28 4:23:49 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 9.63     One year: 11.25
Support: Support1: 8.2    Support2: 8.18
Resistance: Resistance1: 8.25    Resistance2: 9.63
Pivot: 8.22
Moving Average: MA(5): 8.22     MA(20): 8.22
MA(100): 7.42     MA(250): 6.04
MACD: MACD(12,26): 0.01     Signal(9): 0.01
Stochastic oscillator: %K(14,3): 57.14     %D(3): 57.14
RSI: RSI(14): 73.52
52-week: High: 8.25  Low: 4.01
Average Vol(K): 3-Month: 0 (K)  10-Days: 0 (K)

Price, moving averages and Bollinger Bands

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: - -
Low: - -
Close: - -

Company Description

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

Headline News

Sat, 01 Apr 2023
Tazeen Ahmad's Stock Ratings - Benzinga

Wed, 24 Nov 2021
Supernus Pharmaceuticals Completes Acquisition of Adamas ... - GlobeNewswire

Mon, 11 Oct 2021
Supernus bolsters Parkinson's portfolio with $400 mln deal for ... - Reuters

Mon, 09 Aug 2021
Adamas Reports Second Quarter 2021 Financial Results - Business Wire

Thu, 22 Jul 2021
Adamas Announces Issuance of New Patents for GOCOVRI and ... - Business Wire

Mon, 01 Mar 2021
Adamas Pharmaceuticals Announces Closing of Public Offering of ... - Business Wire

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 46 (M)
Shares Float 31 (M)
% Held by Insiders 1.7 (%)
% Held by Institutions 80.3 (%)
Shares Short 1,600 (K)
Shares Short P.Month 2,510 (K)

Stock Financials

EPS -1.61
EPS Est Next Qtl -1.17
EPS Est This Year -3.77
EPS Est Next Year -3.43
Book Value (p.s.) -0.1
Profit Margin (%) -66.82
Operating Margin (%) -45.14
Return on Assets (ttm) -16.4
Return on Equity (ttm) 0
Qtrly Rev. Growth 16.89
Gross Profit (p.s.) 1.58
Sales Per Share 1.8
EBITDA (p.s.) -0.81
Qtrly Earnings Growth 0
Operating Cash Flow -51 (M)
Levered Free Cash Flow -29 (M)

Stock Valuations

PE Ratio -5.14
PEG Ratio 0
Price to Book value -91.34
Price to Sales 4.55
Price to Cash Flow -0.01

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.